Lab Compound Targets Cancer Protein ERG

University of Michigan researchers report an experimental compound that interferes with a protein linked to prostate cancer in laboratory models.

Updated on Nov. 9, 2026 in Cancer

Clear glass culture dishes and an amber dropper bottle sit on a stainless lab bench under cool overhead light. — University of Michigan researchers reported that an experimental compound, PBITE-1, interferes with the cancer-promoting protein ERG in laboratory models, published July 7 in PNAS. AI Illustration. Upload story photo >

Researchers at the University of Michigan identified an experimental compound, PBITE-1, that interferes with the cancer-promoting protein ERG in laboratory models. The findings were published July 7, 2026, in the Proceedings of the National Academy of Sciences.

Why it matters

ERG was long considered undruggable because it appeared to lack molecular pockets where medications typically attach. Most existing prostate cancer therapies target androgen receptors, and tumors often develop resistance to those drugs, so direct targeting of ERG could offer an alternative for patients whose tumors carry the gene fusion.

The laboratory work screened more than 1,600 compounds before refining a candidate into PBITE-1, and the TMPRSS2-ERG gene fusion appears in roughly half of prostate cancer cases among patients of European ancestry. Whether these laboratory effects translate to patients remains unknown.

The players

University of Michigan

A public research university in Ann Arbor, Michigan, whose researchers identified the experimental compound PBITE-1 and conducted the study.

The details

In lab experiments, PBITE-1 inhibited ERG activity, triggered cancer cell death, and reduced cancer cell invasion of surrounding tissue. Researchers found an accessible pocket in the PNT domain of ERG, a site previously thought to lack one.

July 7, 2026: Study published in the Proceedings of the National Academy of Sciences.

Health Landscape

Prostate cancer treatment has relied heavily on androgen receptor-targeting therapies, which tumors often eventually resist. This laboratory work points toward a non-hormonal approach by targeting the ERG protein directly.

PBITE-1 remains a research tool and is not available as a treatment. Patients with prostate cancer should continue to follow their oncologists' guidance on current therapies.

The takeaway

Targeting proteins once considered undruggable may open new options for cancers that resist current hormone-based treatments. Patients and readers should watch for further research before expecting any clinical application.